Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  iobenguane I 131
Find trials that include:  Any drugs shown
Trial Status:  Active
Results 1-13 of 13 for your search:
Start Over
131I-MIBG With Myeloablative Chemotherapy and Autologous Stem Cell Transplantation for the Treatment of High-risk Neuroblastoma
Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 14
Sponsor: Other
Protocol IDs: 87-01-36-6853, NCT00798148
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 1
Sponsor: NCI
Protocol IDs: 04-148, MSKCC-04148, NCT00107289
Iodobenzylguanidine Meta-I131 and Topotecan in Young Patients With Refractory or Relapsed Metastatic Neuroblastoma
Phase: Phase II
Type: Treatment
Status: Active
Age: 1 to 20
Sponsor: Other
Protocol IDs: MIITOP-0607, COL-MIITOP, MIITOP, COL-2006-07, INCA-RECF0633, EUDRACT-2006-004862-15, NCT00960739
A Study Evaluating Ultratrace Iobenguane I 131 (MIBG) in Patients With Malignant Pheochromocytoma/Paraganglioma
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: MIP-IB12B, NCT00874614
131I-MIBG Alone VS. 131I-MIBG With Vincristine and Irinotecan VS131I-MIBG With Vorinistat
Phase: Phase II
Type: Treatment
Status: Active
Age: Over 24 months to less than 30 years
Sponsor: Other
Protocol IDs: N2011-01, NCT02035137
MIBG Therapy for Patients With MIBG Avid Tumors
Phase: Phase II
Type: Treatment
Status: Active
Age: 12 months to 40 years
Sponsor: Other
Protocol IDs: 13-00656, NCH MIBG, NCT02378428
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
Phase: Phase I
Type: Treatment
Status: Active
Age: 16 and over
Sponsor: Other
Protocol IDs: UCL/12/0499, NCT01941849
Diagnosis of Pheochromocytoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Diagnostic
Status: Active
Age: Not specified
Sponsor: NICHD
Protocol IDs: 000093, 00-CH-0093, NCT00004847
Haploidentical Stem Cell Transplantation in Neuroblastoma
Phase: No phase specified
Type: Treatment
Status: Active
Age: 6 months to 21 years
Sponsor: Other
Protocol IDs: 385/2005, NCT00790413
131-I-MIBG Therapy for Refractory Neuroblastoma and Metastatic Paraganglioma/Pheochromocytoma
Phase: No phase specified
Type: Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: 2005-02-4159, CHP-830, NCT01163383
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 1 to 30
Sponsor: NCI, Other
Protocol IDs: ANBL09P1, NCI-2011-01745, CDR0000682629, U10CA180886, U10CA098543, COG-ANBL09P1, NCT01175356
131I-Labeled MIBG for Refractory Neuroblastoma: A Compassionate Use Protocol
Phase: No phase specified
Type: Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: CompUse MIBG, NCT01370330
MIBG for Refractory Neuroblastoma and Pheochromocytoma
Phase: No phase specified
Type: Supportive care, Treatment
Status: Active
Age: 1 and over
Sponsor: Other
Protocol IDs: 2012LS107, NCT01850888
Start Over